Contact us

877-469-1TRM
424-208-8866

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex®) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
HR+/HER2-Negative Metastatic Breast Cancer PD-0332991 (Palbocicilib) III Closed to Accrual